^
Association details:
| Biomarker: | IRF8 overexpression + ER negative |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
Published date:
03/25/2021
Excerpt:
In contrast, in ER-negative BC (TNBC or HER2+), high expression levels of IRF8 was significantly associated with complete pathological response in patients treated with FAC (p = 0.0003) or trastuzumab (p = 0.027) but not CMF (p = 0.746) (Fig. 4).
DOI:
10.1186/s13058-021-01418-7
